NEW YORK (GenomeWeb News) — Illumina will use its Infinium and Beadchip tools to genotype more than 15,000 samples for lung and ovarian cancer research studies organized by Cancer Research UK, the company said today.
For the program to discover genetic risk factors to lung cancer, Illumina will run more than 2,000 samples on the HumanHap550 Beadchip and 5,600 samples on an iSelect Custom Beadchip for the University of Cambridge.
In the ovarian cancer study, conducted for the University of Cambridge and the University of London, Illumina will process more than 2,000 samples on the HumanHap550 and 6,000 samples on the iSelect, the company said.
Illumina said the programs are the third and fourth for which it has been asked to contribute for Cancer Research UK.
Financial terms of the studies, both of which will be funded by Cancer Research UK, were not released.